INV-1120 is under clinical development by Ionova Life Science and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INV-1120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INV-1120 overview

INV-1120 is under development for the treatment of cancer, solid tumors including colorectal, breast, pancreatic, lung cancer, sarcoma and liver cancers. It is administered orally. It acts by targeting EP4.

Ionova Life Science overview

Ionova Life Science, is a biotechnology company that develops anti-tumor and tumor immunomodulatory drugs for the treatment of oncology, immuno-oncology, and cardiac metabolic diseases. The company is headquartered in China.

For a complete picture of INV-1120’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.